In high-grade serous ovarian cancer, increased LPA levels activate LPAR1 to promote Rho-associated protein kinase (ROCK)- and PKC/ERK-induced myosin phosphatase target subunit 1 (MYPT1) phosphorylation, leading to cytoskeletal changes followed by enhanced migration and entosis [77]. This evidence concerns the gene PPP1R12A and ovarian serous adenocarcinoma.